Expert Discusses Immunotherapy Progress in RCC – Targeted Oncology
Targeted Oncology |
Expert Discusses Immunotherapy Progress in RCC
Targeted Oncology McDermott: First, immunotherapy is important. However, it should be rationally applied to patients who are most likely going to benefit. There are patients who get a tremendous benefit, and there are others who get none. We should identify those … |
